NV
CADL icon

Northpond Ventures’s Candel Therapeutics CADL Stock Holding History

Northpond Ventures’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$13.4M Hold
1,935,215
– – 30.72% 3
2024
Q2 		$12M Hold
1,935,215
– – 21.71% 3
2024
Q1 		$3.06M Hold
1,935,215
– – 2.98% 4
2023
Q4 		$2.84M Hold
1,935,215
– – 13.54% 3
2023
Q3 		$1.78M Hold
1,935,215
– – 5.13% 3
2023
Q2 		$2.44M Hold
1,935,215
– – 4.05% 4
2023
Q1 		$2.61M Hold
1,935,215
– – 1.49% 5
2022
Q4 		$3.46M Hold
1,935,215
– – 1.88% 5
2022
Q3 		$6.08M Hold
1,935,215
– – 4.26% 5
2022
Q2 		$6.27M Hold
1,935,215
– – 5.97% 5
2022
Q1 		$9.85M Hold
1,935,215
– – 5.31% 5
2021
Q4 		$15.1M Buy
+1,935,215
New +$18.8M 5.3% 4

Other funds holding CADL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
HFF
Halter Ferguson Financial Carmel, Indiana $456M AUM 49.85% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Northpond Ventures's CADL Position: Q3 2024 in Review

Northpond Ventures held its Candel Therapeutics (CADL) position steady in Q3 2024 at 1,935,215 shares worth $13.4M. The position accounts for 30.72% of the portfolio, ranked #3.

Northpond Ventures first reported a position in CADL in Q4 2021 and has held it in 12 quarters since. The position peaked at $15.1M in Q4 2021. 52 funds tracked by Wall St. Rank hold CADL as of Q3 2024.

  • Northpond Ventures held 1,935,215 shares of Candel Therapeutics worth $13.4M as of Q3 2024.
  • Northpond Ventures left its Candel Therapeutics share count unchanged in Q3 2024.
  • Candel Therapeutics made up 30.72% of Northpond Ventures's portfolio in Q3 2024, its #3 holding.
  • Northpond Ventures first reported a position in Candel Therapeutics in Q4 2021 and has held it in 12 quarters since.
  • Northpond Ventures's Candel Therapeutics position peaked at $15.1M in Q4 2021.
  • 52 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2024.

Based on Northpond Ventures's 13F filing for Q3 2024, filed 14 Nov 2024.